阻断乙型肝炎病毒母婴传播临床管理流程(2021年)

中国肝炎防治基金会; 中华医学会感染病学分会; 中华医学会肝病学分会

doi:10.3969/j.issn.1001-5256.2021.03.007

阻断乙型肝炎病毒母婴传播临床管理流程(2021年)

DOI: 10.3969/j.issn.1001-5256.2021.03.007

基金项目:

深圳市医疗卫生“三名”工程高层次医学团队项目 (SZSM201911001);

国家“十三五”科技重大专项 (2017ZX10201201)

主编：侯金林(南方医科大学深圳医院肝病科)

主审：庄辉(北京大学医学部基础医学院病原微生物学系)

编写专家(按姓氏拼音排序)：

陈仲丹(世界卫生组织驻华代表处)、崔富强(北京大学公共卫生学院)、丁洋(中国医科大学盛京医院感染病科)、窦晓光(中国医科大学盛京医院感染病科)、高云飞(南方医科大学南方医院增城分院妇产科)、韩国荣(南京中医药大学附属南京医院，南京市第二医院妇产科)、侯金林(南方医科大学南方医院感染内科)、贾继东(首都医科大学附属北京友谊医院肝病中心)、李杰(北京大学医学部基础医学院病原微生物学系)、李增德(中国肝炎防治基金会)、刘映霞(深圳市第三人民医院感染科)、刘志华(南方医科大学深圳医院肝病科)、毛青(陆军军医大学西南医院全军感染病研究所)、王爱玲(中国疾病预防控制中心妇幼保健中心)、王维(深圳市宝安区妇幼保健院预防保健科)、魏来(清华大学附属北京清华长庚医院肝胆胰病中心)、夏建红(广东省妇幼保健院保健部)、谢青(上海交通大学医学院附属瑞金医院感染科)、杨希忠(中国肝炎防治基金会)、尹雪如(南方医科大学南方医院感染内科)、张华(首都医科大学附属北京佑安医院妇产科)、张缭云(山西医科大学第一医院感染病科)、张文宏(复旦大学附属华山医院感染科)、庄辉(北京大学医学部基础医学院病原微生物学系)

《阻断乙型肝炎病毒母婴传播临床管理流程(2021年)》编写专家成员名单：

详细信息

通讯作者: 刘志华，Email: zhihualiu@126.com；窦晓光，Email: douxg@sj-hospital.org

中图分类号: R512.62
计量
- 文章访问数: 1522
- HTML全文浏览量: 999
- PDF下载量: 815
- 被引次数: 0
出版历程
- 收稿日期: 2021-01-30
- 录用日期: 2021-01-30
- 出版日期: 2021-03-20

Management algorithm for prevention of mother-to-child transmission of hepatitis B virus(2021)

摘要

- 乙型肝炎 /
- 母婴传播 /
- 临床管理
- Hepatitis B Virus /
- Mother-to-child Transmission /
- Clinical Management

HTML全文

图 1 阻断HBV母婴传播临床管理流程

下载: 全尺寸图片幻灯片

参考文献(28)

[1]	World Health Organization. Global health sector strategy on viral hepatitis 2016-2021[EB/OL]. (2016-06)[2021-02-01]. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.
[2]	Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Management algorithm for interrupting mother-to-child transmission of hepatitis B[J]. J Clin Hepatol, 2017, 33(7): 1214-1217. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2017.07.003 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会. 乙型肝炎母婴阻断临床管理流程[J]. 临床肝胆病杂志, 2017, 33(7): 1214-1217. DOI: 10.3969/j.issn.1001-5256.2017.07.003
[3]	HOU J, CUI F, DING Y, et al. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus[J]. Clin Gastroenterol Hepatol, 2019, 17(10): 1929-1936. e1. DOI: 10.1016/j.cgh.2018.10.007
[4]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.12.007 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007
[5]	Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association; Chinese Society of Perinatal Medicine, Chinese Medical Association. 2020 clinical guidelines on prevention of mother-to-child transmission of hepatitis B virus[J]. J Clin Hepatol, 2020, 36(7): 1474-1481. (in Chinese) DOI: 10.3760/cma.j.cn112141-20200213-00101 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 乙型肝炎病毒母婴传播预防临床指南(2020)[J]. 临床肝胆病杂志, 2020, 36(7): 1474-1481. DOI: 10.3760/cma.j.cn112141-20200213-00101
[6]	World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy[EB/OL]. (2020-07-27)[2021-02-01].https://www.who.int/publications/i/item/978-92-4-000270-8.
[7]	Chinese Society of Hepatology, Chinese Medical Association. Consensus on the management of hepatitis B virus infection in women of childbearing age[J]. J Clin Hepatol, 2018, 34(6): 1176-1180. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.06.008 中华医学会肝病学分会. 感染乙型肝炎病毒的育龄女性临床管理共识[J]. 临床肝胆病杂志, 2018, 34(6): 1176-1180. DOI: 10.3969/j.issn.1001-5256.2018.06.008
[8]	Chinese Society of Hepatology, Chinese Medical Association, China Grade Center. 2019 Chinese practice guideline for prevention and treatment of hepatitis B virus mother-to-child transmission[J]. Chin J Infect Dis, 2019, 37(7): 388-396. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202001019.htm 中华医学会感染病学分会, 中国Grade中心. 中国乙型肝炎病毒母婴传播防治指南[J]. 中华传染病学杂志, 2019, 37(7): 388-396. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202001019.htm
[9]	ZHANG H, PAN CQ, PANG Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J]. Hepatology, 2014, 60(2): 468-476. DOI: 10.1002/hep.27034
[10]	CHEN HL, LEE CN, CHANG CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus[J]. Hepatology, 2015, 62(2): 375-386. DOI: 10.1002/hep.27837
[11]	PAN CQ, DUAN Z, DAI E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374(24): 2324-2334. DOI: 10.1056/NEJMoa1508660
[12]	JOURDAIN G, NGO-GIANG-HUONG N, HARRISON L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B[J]. N Engl J Med, 2018, 378(10): 911-923. DOI: 10.1056/NEJMoa1708131
[13]	ZENG QL, YU ZJ, JI F, et al. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: A multicenter, prospective, observational study[J]. Clin Infect Dis, 2021.[Online ahead of print]
[14]	DING Y, CAO L, ZHU L, et al. Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: A national cohort study[J]. Aliment Pharmacol Ther, 2020, 52(8): 1377-1386. DOI: 10.1111/apt.16043
[15]	YIN X, HAN G, ZHANG H, et al. A real-world prospective study of mother-to-child transmission of HBV in China using a mobile health application (shield 01)[J]. J Clin Transl Hepatol, 2020, 8(1): 1-8. http://www.researchgate.net/publication/339724575_A_Real-world_Prospective_Study_of_Mother-to-child_Transmission_of_HBV_in_China_Using_a_Mobile_Health_Application_Shield_01
[16]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. http://www.sciencedirect.com/science/article/pii/S2468125318300566
[17]	CUI F, WOODRING J, CHAN P, et al. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China[J]. Int J Epidemiol, 2018, 47(5): 1529-1537. http://europepmc.org/abstract/MED/29757383
[18]	National Health Commission of the People's Republic of China. Working standard for prevention of mother-to-child transmission of AIDS, syphilis, and hepatitis B(2020)[EB/OL]. (2020-11-25)[2021-02-01]http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml. ( in Chinese ) 国家卫生健康委员会妇幼健康司. 预防艾滋病、梅毒和乙肝母婴传播工作规范(2020年版)[EB/OL]. (2020-11-25) [2021-02-01 ]http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml.
[19]	PAN CQ, ZOU HB, CHEN Y, et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants[J]. Clin Gastroenterol Hepatol, 2013, 11(10): 1349-1355. http://www.ncbi.nlm.nih.gov/pubmed/23639606
[20]	PENG S, WAN Z, LIU T, et al. Cesarean section reduces the risk of early mother-to-child transmission of hepatitis B virus[J]. Dig Liver Dis, 2018, 50(10): 1076-1080. http://europepmc.org/abstract/MED/29853270
[21]	CHEN HL, CAI JY, SONG YP, et al. Vaginal delivery and HBV mother to child transmission risk after immunoprophylaxis: A systematic review and a meta-analysis[J]. Midwifery, 2019, 74: 116-125. http://www.sciencedirect.com/science/article/pii/S026661381930083X
[22]	SCHILLIE S, VELLOZZI C, REINGOLD A, et al. Prevention of hepatitis B virus infection in the United States: Recommendations of the advisory committee on immunization practices[J]. MMWR Recomm Rep, 2018, 67(1): 1-31. http://www.ncbi.nlm.nih.gov/pubmed/29939980
[23]	CHEN X, CHEN J, WEN J, et al. Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus[J]. PLoS One, 2013, 8(1): e55303. http://pubmedcentralcanada.ca/pmcc/articles/PMC3557270/?lang=fr
[24]	SHI Z, YANG Y, WANG H, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: A meta-analysis and systematic review[J]. Arch Pediatr Adolesc Med, 2011, 165(9): 837-846. http://labs.europepmc.org/abstract/MED/21536948
[25]	EHRHARDT S, XIE C, GUO N, et al. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: A review of the evidence[J]. Clin Infect Dis, 2015, 60(2): 275-278. http://cid.oxfordjournals.org/content/60/2/275.full
[26]	YI W, PAN CQ, LI MH, et al. The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B[J]. Am J Gastroenterol, 2018, 113(5): 686-693. http://www.nature.com/articles/s41395-018-0010-2
[27]	Antiretroviral Pregnancy Registry Interim Report for 1 January 1989-31 January 2020[EB/OL].[2021-02-01]. http://www.apregistry.com/forms/exec-summary.pdf.
[28]	WEN WH, CHEN HL, SHIH TT, et al. Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study). Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate[J]. J Hepatol, 2020, 72(6): 1082-1087.